X4 Pharmaceuticals, Inc. (XFOR)
3.095
-0.02
(-0.80%)
USD |
NASDAQ |
Nov 16, 09:42
X4 Pharmaceuticals Total Assets (Quarterly) : 231.82M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 231.82M |
| June 30, 2026 | 253.06M |
| March 31, 2026 | 270.28M |
| December 31, 2025 | 290.46M |
| September 30, 2025 | 163.56M |
| June 30, 2025 | 105.17M |
| March 31, 2025 | 130.01M |
| December 31, 2024 | 146.45M |
| September 30, 2024 | 178.16M |
| June 30, 2024 | 210.61M |
| March 31, 2024 | 112.18M |
| December 31, 2023 | 147.26M |
| September 30, 2023 | 173.29M |
| June 30, 2023 | 173.40M |
| March 31, 2023 | 124.40M |
| December 31, 2022 | 155.59M |
| September 30, 2022 | 113.41M |
| June 30, 2022 | 81.02M |
| March 31, 2022 | 99.62M |
| December 31, 2021 | 117.18M |
| Date | Value |
|---|---|
| September 30, 2021 | 120.52M |
| June 30, 2021 | 141.66M |
| March 31, 2021 | 161.04M |
| December 31, 2020 | 122.87M |
| September 30, 2020 | 133.13M |
| June 30, 2020 | 142.53M |
| March 31, 2020 | 153.72M |
| December 31, 2019 | 160.70M |
| September 30, 2019 | 109.54M |
| June 30, 2019 | 133.51M |
| March 31, 2019 | 62.55M |
| December 31, 2018 | 9.944M |
| September 30, 2018 | 45.90M |
| June 30, 2018 | 57.21M |
| March 31, 2018 | 69.22M |
| December 31, 2017 | 81.25M |
| September 30, 2017 | 37.16M |
| June 30, 2017 | 39.52M |
| March 31, 2017 | 10.98M |
| December 31, 2016 | 7.604M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Oncolytics Biotech, Inc. | 5.832M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.166B |
| Anixa Biosciences, Inc. | 15.07M |
| Vicapsys Life Sciences, Inc. | 0.1325M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 92.93M |
| Shareholders Equity (Quarterly) | 138.88M |
| Debt to Equity Ratio | 0.5558 |
| Current Ratio | 13.22 |
| Net Debt Paydown Yield | 0.06% |